NDAQ:CMPS - Post Discussion
Post by
AwareInvestor on Jun 28, 2021 7:38am
Compass Pathways Closes Enrollment For Phase IIb Psilocybin
Compass Pathways this morning provided a brief update to the market on the latest status of its ongoing phase IIb psilocybin therapy trial. The trials are being conducted to test the efficacy of psilocybin against treatment-resistant depression.
Be the first to comment on this post